E.i. Dupont De Nemours and Company

William K Schmidt

Dewey H Smith, Jr

Vernon G Vernier

John R Dudzinski

Christine Smith

Geraldine L Baker

Pharmaceutical compositions of narcotic analgesics and ibuprofen have been found to exhibit unexpectedly enhanced analgesic activity by applying an analysis model which considers data characterizing the analgesic effect of both the pure components as well as the fixed dose ratio combinations. This synergism enables the use of lower doses of either or both drugs with a concomitant reduction in risk of possible side effects.

Analgesic mixture of oxycodone and ibuprofen

Pharmaceutical compositions of nalbuphine and indomethacin have been found to exhibit unexpectedly enhanced analgesic activity by applying an analysis model which considers data characterizing the analgesic effect of both the pure components as well as the fixed dose ratio combinations. This synergism enables the use of lower doses of either or both drugs with a concomitant reduction in risk of possible side effects.

Analgesic mixture of nalbuphine and indomethacin

Pharmaceutical compositions of nalbuphine and zomepirac have been found to exhibit unexpectedly enhanced analgesic activity by applying an analysis model which considers data characterizing the analgesic effect of both the pure components as well as the fixed dose ratio combinations. This synergism enables the use of lower doses of either or both drugs with a concomitant reduction in risk of possible side effects.

Analgesic mixture of nalbuphine and zomepirac

Pharmaceutical compositions of nalbuphine and flurbiprofen have been found to exhibit unexpectedly enhanced analgesic activity by applying an analysis model which considers data characterizing the analgesic effect of both the pure components as well as the fixed dose ratio combinations. This synergism enables the use of lower doses of either or both drugs with a concomitant reduction in risk of possible side effects.

Analgesic mixture of nalbuphine and flurbiprofen

Pharmaceutical compositions of nalbuphine and ibuprofen have been found to exhibit unexpectedly enhanced analgesic activity by applying an analysis model which considers data characterizing the analgesic effect of both the pure components as well as the fixed dose ratio combinations. This synergism enables the use of lower doses of either or both drugs with a concomitant reduction in risk of possible side effects.

Analgesic mixture of nalbuphine and ibuprofen

Pharmaceutical compositions of nalbuphine and sulindac have been found to exhibit unexpectedly enhanced analgesic activity by applying an analysis model which considers data characterizing the analgesic effect of both the pure components as well as the fixed dose ratio combinations. This synergism enables the use of lower doses of either or both drugs with a concomitant reduction in risk of possible side effects.

Analgesic mixture of nalbuphine and sulindac

Pharmaceutical compositions of nalbuphine and tiflamizole have been found to exhibit unexpectedly enhanced analgesic activity by applying an analysis model which considers data characterizing the analgesic effect of both the pure components as well as the fixed dose ratio combinations. This synergism enables the use of lower doses of either or both drugs with a concomitant reduction in risk of possible side effects.

Analgesic mixture of nalbuphine and tiflamizole

Pharmaceutical compositions of nalbuphine and 4,5-bis(4-methoxyphenyl)-2-(trifluoromethylsulfonyl)-1H-imidazole have been found to exhibit unexpectedly enhanced analgesic activity by applying an analysis model which considers data characterizing the analgesic effect of both the pure components as well as the fixed dose ratio combinations. This synergism enables the use of lower doses of either or both drugs with a concomitant reduction in risk of possible side effects.

Analgesic mixture of nalbuphine and

A composition consisting essentially of nalbuphine and acetylsalicylic acid, derivative or salt thereof, gives unexpectedly enhanced analgetic activity.

Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or

Unexpectedly enhanced relief of pain in a mammal is obtained by oral administration of a composition consisting essentially of zomepirac or a pharmaceutically suitable salt thereof and acetaminophen.

Growing community of inventors

Wilmington, DE, United States of America

William K Schmidt